



12 November 2024

AFT appoints Allison Yorston as independent director

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of Allison Yorston as an independent non-executive director.

The appointment fills the vacancy left by Anita Baldauf who retired from the board at the shareholders meeting in August.

Chair David Flacks says: "We are delighted to welcome Allison to our board. She has outstanding experience as a senior marketing executive in Australia and New Zealand and is currently the Chief Marketing Officer for Suntory Beverage and Food Oceania.

"Allison's senior marketing experience is highly relevant to AFT as we grow and consolidate our position in Australasia and build our presence internationally with our Maxigesic® pain relief and other medications."

Allison says: "I am excited by the opportunity to assist AFT with its growth aspirations and honoured to join the experienced board. I look forward to utilising my strategic, commercial and marketing skillset for positive impact."

The board has determined that Allison Yorston is an Independent Director (within the meaning of the NZX Listing Rules).

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:

Investors

Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media

Richard Inder
The Project
Tel: +64 21 645 643

About AFT Pharmaceuticals

AFT is a growing New Zealand based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products,

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN: ARBN 609 017 969 investor.relations@aftpharm.com

and includes patented, branded, and generic drugs¹. Our business model is to develop and in-license products for in our markets of Australia, New Zealand, Singapore, Malaysia, Hong Kong, USA, Canada, EU ex Ireland and UK, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.